**Name of journal:** ***World Journal of*** ***Gastroenterology***

**ESPS Manuscript NO: 29738**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Cohort Study***

**Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal bacterial overgrowth: Results of a retrospective cohort study**

Brechmann T *et al.* Main contributors of SIBO

Thorsten Brechmann, Andre Sperlbaum, Wolff Schmiegel

**Thorsten Brechmann, Andre Sperlbaum, Wolff Schmiegel,** Department of Gastroenterology and Hepatology, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH, Ruhr-University Bochum, 44789 Bochum, Germany

**Author contributions:** Brechmann T guarantor of the article; Conception and design of the study, data analysis and interpretation, supervision, drafting the manuscript; Thorsten Brechmann approved the final manuscript; Sperlbaum A Conducting the study, acquisition of data, analysis and interpretation; Andre Sperlbaum approved the final manuscript; Schmiegel W supervision, revision of the manuscript, support in terms of gastroenterology, Schmiegel W approved the final manuscript.

**Institutional review board statement:** The study was reviewed and approved by the Institutional Review Board of the Ruhr-University Bochum (Registration number: 4864-13).

**Conflict-of-interest statement:** The authors declare that there is no actual or potential conflict of interest related to the work.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Thorsten Brechmann, MD,** Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH, Ruhr-University Bochum, Department of Gastroenterology and Hepatology, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany. [thorsten.brechmann@rub.de](mailto:thorsten.brechmann@rub.de)

**Telephone**: +49-234-3023411

**Fax**: +49-234-3026707

**Received:** August 26, 2016

**Peer-review started:** August 28, 2016

**First decision:** October 20, 2016

**Revised:** October 22, 2016

**Accepted:** November 15, 2016

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To identify a set of contributors, and weight and rank them on a pathophysiological basis.

***METHODS***

Patients who have undergone a lactulose or glucose hydrogen breath test to rule out small intestinal bacterial overgrowth (SIBO) for various clinical symptoms, including diarrhoea, weight loss, abdominal pain, cramping or bloating, were seen as eligible for inclusion in a retrospective single-centre study. Clinical data such as co-morbidities, medication, laboratory parameters and other possible risk factors have been identified from the electronic data system. Cases lacking or with substantially incomplete clinical data were excluded from the analysis. Suspected contributors were summarised under four different pathophysiological pathways (impaired gastric acid barrier, impaired intestinal clearance, immunosuppression and miscellaneous factors including thyroid gland variables) and investigated using the *χ*2 test, Student’s *t*-test and logistic regression models.

***RESULTS***

A total of 1809 patients who had undergone hydrogen breath testing were analysed. Impairment of the gastric acid barrier (gastrectomy, odds ratio: OR = 3.5, PPI therapy OR = 1.4), impairment of intestinal clearance (any resecting gastric surgery OR = 2.6, any colonic resection OR = 1.9, stenosis OR = 3.4, gastroparesis OR = 3.4, neuropathy 2.2), immunological factors (any drug-induced immunosuppression OR = 1.8), altered thyroid gland metabolism (hypothyroidism OR = 2.6, levothyroxine therapy OR = 3.0) and diabetes mellitus (OR = 1.9) were associated significantly to SIBO. Any abdominal surgery, ileocecal resection, vagotomy or IgA-deficiency did not have any influence, and a history of appendectomy decreased the risk of SIBO. Multivariate analysis revealed gastric surgery, stenoses, medical immunosuppression and levothyroxine to be the strongest predictors. Levothyroxine therapy was the strongest contributor in a simplified model (OR = 3.0).

***CONCLUSION***

The most important contributors for the development of SIBO in ascending order are immunosuppression, impairment of intestinal clearance and levothyroxine use, but they do not sufficiently explain its emergence.

**Key words**: Bacterial overgrowth syndrome; Hydrogen breath tests; Hypothyroidism; Intestinal motility; Immunosuppression

**©** **The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Several contributors to small intestinal overgrowth have been described, but the impact of particular risk factors is poorly understood. We aimed to determine the influence of several pathomechanisms, such as impaired gastric acid barrier function, impaired intestinal clearance, impairment of defence mechanisms and miscellaneous factors, as well as to weight and rank a large set of potential contributors by means of a retrospective cohort study of 1809 consecutive patients who had undergone a hydrogen breath test to rule out small intestinal bacterial overgrowth. Overall, levothyroxine therapy, impaired intestinal clearance and immunosuppression are the strongest contributors, while an impaired gastric acid barrier only plays a minor role.

Brechmann T, Sperlbaum A, Wolff Schmiegel W. Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal overgrowth: results of a retrospective cohort study. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

Small intestinal bacterial overgrowth (SIBO) is defined as an increase in the number of bacteria in the upper gastrointestinal tract. The aetiology and pathogenesis of SIBO are incompletely understood. It is believed that endogenous defence mechanisms prevent abundant microbial growth in the small intestine[1] under physiological conditions, so that the development of SIBO is usually seen to be associated with disorders of protective antimicrobial mechanisms, anatomical abnormalities or motility disorders. High recurrence rates after successful antibiotic treatment emphasise the need to identify aetiological factors in order to potentially remedy the situation[2].

***Impairment of the gastric acid barrier function***

Gastric acidity constitutes an effective barrier against the invasion of ingested microorganisms. Although the data is weak and contradictory, reduction of the acid barrier function, as suspected for atrophic gastritis[3,4], use of proton pump inhibitors[5] and gastrectomy[6,7], is thought to lead to higher microbial loads in the small intestine.

***Impaired intestinal clearance***

Although several reviews highlight anatomic pathologies associated with small intestinal obstruction and stagnation, for example, strictures, adhesions, tumours of the small bowel, duodenal and jejunal diverticula, previous abdominal surgery such as blind loop syndrome after Billroth-II or Roux-en-Y procedure, or bariatric bypass surgery, to be associated with SIBO, only very few or no data at all support these hypotheses. Overall abdominal surgery was not associated with SIBO in a small retrospective study[8]. However, gastrectomy and bariatric surgery in morbid obese patients often leads to the development of SIBO[6,7,9]; the existence of blind loops might be the common mechanism. Additionally, conditions that predispose stool reflux, such as ileocecal resection or low ileocecal valve pressure, are discussed as SIBO predisposing factors[10].

More evidence exists concerning impaired motility, such as small intestinal pseudo-obstruction and several neurological diseases or diabetes[1,11]. It has been demonstrated for a long time that a subset of patients with SIBO show reduced motility[12] with fewer phase III contractions of the migrating motor complexes and a mutual influence since eradication of bacterial overgrowth improved motility[13]. Gastroparesis, which has been shown to be associated with SIBO[14,15], might indicate gastrointestinal autonomous neuropathy. Otherwise, little is known about the effect of drugs used to deteriorate intestinal motility, even though “narcotics” have been identified as contributing towards SIBO[16].

***Impairment of immunological mechanisms***

Data about the role of the immune system are also scarce and contradictory. A higher bacterial load of jejunal aspirates have been shown in ten paediatric patients with IgA deficiency and seven with other immune syndromes[17], while data concerning adult patients are lacking. In fact, medical therapy is the most common reason for immunosuppression in adults, though SIBO was not shown to be associated with immunosuppressive medication in patients with Crohn’s disease[18,19], while steroids predisposed to SIBO in a more unselected cohort[20].

***Miscellaneous factors***

Various other diseases and disorders have been described as being associated with or complicated by SIBO, such as alcohol consumption[21], liver cirrhosis[22,23,24,24], non-alcoholic steatohepatitis[26], hypothyroidism[27] or chronic pancreatitis[28].

In summary, several contributors to the development of SIBO have been proposed, but only a few have been proven in clinical studies, which often refer to small and selected cohorts. Additionally, it is uncertain which pathomechanisms are more and which are less important contributors. We aimed, therefore, to (1) evaluate a larger set of potential risk factors; (2) arrange them in a pathogenetic model; and (3) rank the contributors referring to their particular weight in a largely unselected cohort of SIBO and non-SIBO patients in an extensive retrospective cohort study.

**MATERIALS AND METHODS**

***Study population***

We conducted a retrospective single-centre study of patients undergoing lactulose or glucose hydrogen breath testing between 1995 and 2010, who were referred to the Department of Gastroenterology at the University Hospital Bergmannsheil Bochum, Germany. Patients underwent breath tests to rule out SIBO for various clinical symptoms, including diarrhoea, weight loss, abdominal pain, cramping or bloating. All cases with an original examination report available were considered eligible for the study. Patients with both missing or incomplete clinical data, or incomplete or aborted examination were excluded (Table 1). Patients with multiple hydrogen breath tests within the study period were considered only once.

***Clinical work-up and reference standard***

All patients underwent a hydrogen breath test with lactulose, glucose or both in combination. Additionally, patients underwent a routine diagnostic work-up following a clinical algorithm by a symptom-based diagnostic approach including clinical evaluation (history, symptomatology, clinical examination, complaints, clinical course), laboratory including stool testing, and endoscopy (ileocolonoscopy, esophagogastroduodenoscopy) including histopathology and transabdominal ultrasound. Further diagnostic tools may have been used, for example, small bowel magnetic resonance imaging, endoscopic ultrasound, small bowel endoscopy, manometry or extended function testing.

*Hydrogen breath test*

Breath tests were performed according to a standardised protocol with either 25 g lactulose or 75 g glucose in 300 mL water, respectively. Only one test was performed per day. Breath samples were collected using an AlveoSamplerTM (Campro Scientific GmbH, Germany) every 10 min over a period of 2 h. In cases of failed hydrogen exhalation during a lactulose breath test, collecting periods were extended up to 180 min.

***Analysis of breath test examinations***

An increase in hydrogen of at least 20 ppm was considered positive; for a lactulose breath test, this increase had to have occurred at least 15 min before a sustained rise in hydrogen exhalation indicating colonic lactulose metabolism.

*Clinical data acquisition*

Additional clinical data was collected from the electronic database. Cases lacking or with substantially incomplete clinical data were excluded from the analysis.

*Statistical analysis*

Statistical analysis was performed with SPSS 23 (IBM, Armonk, United states). The χ2 test was used to determine statistical significance with categorial variables, and the Student’s *t*-test for metric variables. Regarding the multivariate analysis, binary logistic regression was performed in each pathophysiological pathway suspected separately (hypo-/achlorhydria, impaired clearance, immunosuppression, thyroid gland variables and miscellaneous factors) and with statistically significant variables in a summarising model. Finally, the highest ranked parameter of each particular section was chosen to calculate a simplified ranking model. The odds ratios (OR) and 95% confidence intervals were estimated for specific clinical factors using logistic regression models. Analysis was considered significant with a *P* value ≤ 0.05.

*Ethical considerations*

The study was approved by the institutional review board (registration number 4864-13). Informed consent was obtained from the patients before particular examinations.

**RESULTS**

***Basic characteristics***

A total of 3715 hydrogen breath test examinations was considered eligible, 1586 of these were excluded due to missing or insufficient clinical information, and 320 records were excluded due to repetitive examinations of the same subject (Figure 1), therefore, our study population in summary contained a total of 1809 patients, with a slight, but not significant excess of women (Table 1). The age did not differ significantly between the gender groups. The overall basic characteristics of the patients were equally distributed as displayed, but patients with SIBO took slightly more drugs (1.32% *vs* 1.61%), especially spasmolytics and antiemetics (4.1% *vs* 14.9% and 8.8% *vs* 11.6%, respectively). Supplementation of iron and cobalamin was more common in SIBO patients.

The SIBO patients were more likely to undergo small bowel visualisation (video capsule endoscopy 4.0% *vs* 1.2%) while colonoscopy was performed more often in the non-SIBO group (57.1% *vs* 65.4%).

***Suspected risk factor analysis***

**Hypo-/Achlorhydria:** Patients with a history of total gastrectomy were more likely to develop SIBO (2.3% *vs* 0.7%). The OR was 3.45 (Table 2). Current PPI therapy led to a higher SIBO rate (40.0% *vs* 31.8%), although the effect was small (OR = 1.43).

**Impaired bowel clearance – anatomical alterations and surgery:** Overall abdominal surgery was not associated with a higher risk of SIBO (Table 3). Patients after gastrectomy and patients with a history of any resecting gastric surgery had a higher prevalence of SIBO (6.9% *vs* 2.8%, OR = 2.60). By contrast, neither Bilroth-II resection nor the existence of blind intestinal loops exhibited a higher prevalence of SIBO, although the latter group showed a tendency (4.6% *vs* 2.5%). Loss of the ileocecal valve did not increase risk, while a history of appendectomy occurred more often in non-SIBO patients (8.2% *vs* 4.6%), indicating a protective factor with an OR of 0.46. On the other hand, functional appendectomy (including those patients with ileocecal resection) did not show such an effect. Obstetric surgery, sigmoid and small intestinal resection did not affect development of SIBO, while any colonic resection was associated with an OR of 1.93 (10.9% *vs* 5.9%). Cholecystectomy tended to be protective (4.6% *vs* 7.8%). Stenoses of the intestinal tract were associated with SIBO (5.7% *vs* 1.8%) with an OR of 3.36.

**Impaired bowel clearance – functionally impaired clearance:** Impaired motility (9.7% *vs* 0.6%), gastroparesis (2.9% *vs* 1.5%) and neuropathy (5.1% *vs* 2.4%), but not vagotomy were associated with higher risks of SIBO; referring to Table 3, the ORs were 5.16, 3.40 and 2.22, respectively. Prevalence of SIBO tended to be higher under opioid medication, but did not achieve statistical significance (5.7% *vs* 3.4%).

**Immunological factors:** Immunoglobulin deficiency did not change the risk of developing SIBO (Table 4), while the use of steroids (20.6% *vs* 13.6%) or classical immunosuppressants (4.6% *vs* 1.9%), any immunosuppressive therapy (22.3% *vs* 14.1%) and the combination of steroids and immunosuppressants led to a higher risk of SIBO (4.0% *vs* 1.4%). The OR was highest in the combination group (steroid plus immunosuppressant: OR = 2.92).

***Other factors***

**Thyroid gland metabolism:** As referred to in Table 5, patients with hypothyroidism and patients with levothyroxine therapy showed a higher prevalence of SIBO (9.7% *vs* 4.0% and 17.1% *vs* 6.5%, respectively) while a history of thyroidectomy slightly failed to.

**Miscellaneous:** Diabetes mellitus was associated with a 1.90-fold increased risk of developing SIBO (14.3% *vs* 8.1%; Table 5). Sigmoid, but not colonic diverticulosis was associated with a lower prevalence of SIBO (4.6% *vs* 9.2%).

**Multivariate analysis:** The different pathomechanistic pathways were tested in a binary logistic regression analysis. The strongest particular independent variables were PPI therapy and gastrectomy for hypo- or achlorhydria. Both showed statistical significance with an OR of 1.45 and 3.64, respectively.

All variables which potentially impair intestinal clearance were studied in a further model. Any resecting gastric surgery, stenoses, gastroparesis and any colonic resection were significantly associated with the presence of SIBO (*P* < 0.05): the ORs were 6.49, 3.19, 3.25 and 1.85, respectively, while gastrectomy, neuropathy, existence of blind loops, appendectomy and cholecystectomy were not.

The model for immunosuppression did not show any significant parameters. Binary logistic regression for thyroid gland variables proved statistically significant for levothyroxine use with an OR of 2.8, while thyroidectomy and hypothyroidism did not. The only significant parameter in the model of miscellaneous variables was sigmoid diverticulosis with an OR of 0.453; the other factors were opioid use, smoking, diabetes and ulcerative colitis.

Finally, the variables PPI therapy, history of gastrectomy, history of any resecting gastric surgery, presence of stenoses, use of levothyroxine, presence of diabetes, neuropathy or gastroparesis, medical immunosuppression and therapy with opioids have been included in a summarising model (Table 6). The Omnibus test results are highly significant (*P* < 0.001). The Hosmer-Lemeshow test (*P* = 0.500) indicates that the independent variables form a good model to predict SIBO (54 cases observed, 56 cases expected); Nagelkerke’s R2 was 0.070. Variables with significant influence were any resecting gastric surgery (*P* = 0.037, OR = 2.40), stenoses (*P* = 0.008, OR = 2.81), any medical immunosuppression (*P* = 0.036, OR = 1.53), levothyroxine therapy (P < 0.001, OR = 2.92) and presence of sigmoid diverticulosis (*P* = 0.028, OR = 2.30).

Of the variables “impairment of acid barrier” (PPI therapy and gastrectomy), “impairment of intestinal clearance” (history of any resecting gastric surgery, presence of stenoses, gastroparesis), “impairment of immune response” (any medical suppression) or hypothyroidism (levothyroxine supplementation), the latter three were significantly associated with SIBO with odds ratios of 2.2, 1.6 and 3.0, respectively, in a simplified model in which every factor that was significant in the particular logistic regression was summarised (Table 7).

**DISCUSSION**

The pathogenesis of SIBO and underlying predisposing conditions are insufficiently understood. Several risk factors have been proposed, but most studies refer to one or very few variables in selected populations. Furthermore, no study investigated and ranked the underlying main pathomechanistic pathways. In this retrospective study, we sought to identify, categorise and, finally, rank the influence of potential contributors to SIBO in a large and widely unselected population. Three main pathogenetic pathways have been hypothesised: hypo- or achlorhydria, impaired intestinal clearance and immunosuppression. Further factors of unknown action, such as hypothyroidism, inflammatory bowel disease or sigmoid diverticulosis, were also considered.

***Hypo- /Achlorhydria***

Both PPI therapy and, even more predominantly, gastrectomy were significantly associated with SIBO (Table 2). These findings coincide with results in the literature, although glucose hydrogen breath tests usually failed to find an association between SIBO and PPI therapy[5-7]. Consequently, gastrectomy was a stronger predictor of SIBO in binary regression analysis than PPI therapy (OR 3.6 *vs* 1.5). Moreover, the altered anatomical situation with the establishment of blind loops might play a role in the development of SIBO after gastrectomy, although our data does not confirm blind loops as a pathophysiological factor (Table 3). However, both variables are of minor relevance and lost their significance in multivariate models.

***Impaired intestinal clearance***

Anatomic modifications which might lead to impairment of intestinal clearance derive mostly from surgery, but, similar to a smaller retrospective study by Petrone *et al*[8], overall abdominal surgery was not associated with an increased risk of SIBO, neither were sigmoid nor ileocecal resection nor obstetric surgery (Table 3). Our data, therefore, does not confirm the previously assumed protective function of the ileocecal valve[10]. By contrast, total gastrectomy, any resecting gastric surgery and stenoses which lead to stasis of the chymus contributed to the development of SIBO with odds ratios between 1.9 and 3.6. Since blind loops of any reason were astonishingly not associated to SIBO, the combination of intestinal diversion and loss of acid barrier is of greater relevance.

Since small intestinal motility is difficult to quantify as a promoter of clearance, this effect might be estimated by measuring gastroparesis as a surrogate parameter. This association has already been described in other studies[14,15]. Our data shows that conditions believed to be associated with intestinal paralysis, such as polyneuropathy, are indeed associated with gastroparesis (*P* < 0.001, χ2 test). Both are linked to SIBO, but multivariate analysis reveals that gastroparesis is the better parameter (Tables 3 and 7), by which it is easier to quantify than intestinal motility itself.

Any resecting gastric surgery, stenoses and gastroparesis were associated with SIBO in binary regression analysis, and the particular OR varied between 1.8 and 6.5, with the highest value for overall gastric surgery.

***Immunosuppression***

Data about the role of the immune system is scarce, biased and contradictory. Higher bacterial loads of jejunal aspirates have been shown in ten paediatric patients with IgA deficiency and seven with other immune syndromes[17]. Therapy with immunosuppressives in Crohn’s disease did not increase the occurrence of SIBO[18,19], while steroids did so in a more unselected cohort by lowered levels of IgA, as hypothesised by the authors[20]. Since neither IgA nor IgG deficiency were associated to SIBO in our analysis, we conclude that IgA deficiency does not – either directly or indirectly triggered by steroids – contribute to SIBO in adult patients. On the other hand, therapy with classical immunosuppressants, such as azathioprine or methotrexate, with steroids alone or in combination with immunosuppressants leads to a higher risk of SIBO (Table 4), while other anti-inflammatory drugs, such as 5-aminosalicylates, that usually serve as reference did not change the risk, suggesting that immunosuppression is the underlying mechanism. The association was quite loose, with odds ratios between 1.6 and 2.5, but was still found to be a minor contributor to SIBO in the multivariate analysis therapy with any immunosuppressant drug, i.e. azathioprine, methotrexate or steroids.

***Thyroid gland metabolism***

Hypothyroidism and levothyroxine therapy are the most strongly associated to SIBO in our cohort. A case control study by Lauritano *et al*[27] has already revealed a high prevalence of SIBO in patients with autoimmune thyroiditis and hypothyroidism, but the influence of the autoimmune process was a questionable biasing factor. Multivariate analysis confirmed that levothyroxine therapy is a stronger predictor of SIBO than hypothyroidism. The underlying mechanism is unclear. One might speculate that hypothyroidism leads to hypomotility, but, surprisingly, levothyroxine therapy was even more associated to SIBO and not able to reverse the effect of hypothyroidism.

***Miscellaneous variables***

Although SIBO was more frequent in patients with cholecystectomy in one study[29], our data propose that cholecystectomy is a protective factor. This finding is supported by another retrospective study[21]. We assume that the prolonged contact time and the optimised environment due to constant excretion of the bile allow its antimicrobial effects to better develop as a potential underlying mechanism.

Though reported as a slight risk factor for the development[20] and recurrence [2] of SIBO, in our cohort, appendectomy was prevalent more often in non-SIBO patients (8.2% *vs* 4.6%, *P* = 0.027, χ2 test), indicating that it is a protective factor with an OR of 0.455. The potential underlying mechanism is unclear, but an effect on other bowel diseases, especially ulcerative colitis, has already been shown[30].

As in previous studies[11], diabetes was associated with SIBO, but lost its effect in multivariate analysis (Tables 5, 7 and 10), proposing that diabetes does not contribute directly, but as a consequence of complications such as neuropathy, which is supported by a strong association between diabetes and gastroparesis (*P* < 0.001, χ2 test).

***Weighting of the particular etiological pathways***

Binary logistic regression reveals the history of any resecting gastric surgery, stenoses, medical immunosuppression, levothyroxine supplementation or presence of sigmoid diverticulosis to be associated to a higher risk of SIBO (Table 6). In this model, a reduced gastric acid barrier lost its significance as a pathogenetic factor. The highest odds ratios were seen for factors that, similar to stenoses, lead to impaired clearance, on the one hand, and supplementation of levothyroxine, on the other hand (Table 6). In this model, several independent factors of impaired clearance, but only one of immunosuppression and thyroid gland metabolism were confirmed.

In a simplified model in which any impairment of the acid barrier, of intestinal clearance, or of immune response and hypothyroidism were analysed, the impaired acid barrier again lost its significance (Table 7). Hypothyroidism or, respectively, levothyroxine therapy was most the important single factor with an odds ratio of 3.0; the second most important was impaired intestinal clearance (OR = 2.2) and the third most important was impaired immune response (OR = 1.6).

***Limitations***

Due to selective information on outpatients, our study population consists mostly of inpatients, which might have led to a certain bias. Furthermore, the retrospective study design itself is associated with certain limitations, such as primary lack or secondary loss of information, uncertainty of adherence to protocols or unequal power between groups. We, therefore, included only a subset of possible contributors that were available for retrospective analysis. Diagnosis of SIBO referred to clinical work-up and is mainly based on the hydrogen breath test. That approach covers advantages such as independence from jejunal, which is neither well standardised nor able to culture all respective flora, but also disadvantages such as unclear reliability. Finally, not every potential contributor who underwent clinical work-up was carefully ruled out in every subject. Therefore, some suspected contributors, such as gastroparesis or polyneuropathy, might be underreported.

To the best of our knowledge, this is the largest study that investigated contributors to SIBO in a widely spread population. The results confirm that impairment of acid barrier, impaired intestinal clearance, immunosuppression and especially levothyroxine therapy/hypothyroidism to be important pathomechanistic pathways for the development of SIBO. The strongest effects derive from levothyroxine supplementation/hypothyroidism, although the relevant mechanism of action remains unclear, and intestinal stasis.

**ACKNOWLEDGEMENTS**

We would like to thank the staff of the Department of Gastroenterology and Hepatology for their support throughout the study. Special thanks go to the members of the laboratory of gastroenterological function testing, i.e. A. Beckmann, A. Kuehl, C. Nolte and E. Dretaki-Schnackenberg.

**COMMENTS**

***Background***

Small intestinal bacterial overgrowth (SIBO) is characterised by an excessive colonisation of the small bowel. Pathogenesis is incompletely understood, but recurrence rates after successful antibiotic treatment are high. Several risk factors that contribute to the development have been proposed, and some potential contributors have been shown in mostly small studies with selected populations.

***Research frontiers***

SIBO is defined as an increase in the number of bacteria in the upper gastrointestinal tract. Related symptoms are nonspecific and include bloating, abdominal pain or diarrhea, and thus overlap widely with symptoms of irritable bowel syndrome. Diagnosis of SIBO still is a challenging clinical problem. Several methods are available, but up to now, a standard of choice is not yet defined. Furthermore, the pathogenesis of SIBO is incompletely understood and studies are needed to identify etiology and pathogenesis. Therapy of SIBO is unsatisfactory; empiric and often broad-spectrum antibiotic treatment fails frequently and suffers from high recurrence rates.

***Innovations and breakthroughs***

The aim of the study was to identify a set of risk factors, weight and rank them on a pathophysiological basis in a large and widely unselected population. Potential contributors were summarised under four different pathophysiological pathways. Impairment of the gastric acid barrier (gastrectomy, odds ratio: OR = 3.5, PPI therapy OR = 1.4), impairment of intestinal clearance (any resecting gastric surgery OR = 2.6, any colonic resection OR = 1.9, stenosis OR = 3.4, gastroparesis OR = 3.4, neuropathy 2.2), immunological factors (any drug-induced immunosuppression OR = 1.8), altered thyroid gland metabolism (hypothyroidism OR = 2.6, levothyroxine therapy OR = 3.0) and diabetes mellitus (OR = 1.9) were associated significantly to SIBO. Any abdominal surgery, ileocecal resection, vagotomy or IgA-deficiency did not have any influence, and a history of appendectomy decreased the risk of SIBO. Multivariate analysis revealed gastric surgery, stenoses, medical immunosuppression and levothyroxine to be the strongest predictors. Levothyroxine therapy was the strongest contributor in a simplified model (OR = 3.0).

***Applications***

The most important contributors for the development of SIBO in ascending order are immunosuppression, impairment of intestinal clearance and levothyroxine use, but they do not sufficiently explain its emergence. The knowledge of respective contributors potentially enables to intervene in the pathogenesis and therefore minimise the risk of recurrence.

***Terminology***

SIBO is characterised by an increase of bacterial colonisation of the small bowel.

***Peer-review***

It is an interesting and well performed study.

**REFERENCES**

1 **Bures J**, Cyrany J, Kohoutova D, Förstl M, Rejchrt S, Kvetina J, Vorisek V, Kopacova M. Small intestinal bacterial overgrowth syndrome. *World J Gastroenterol* 2010; **16**: 2978-2990 [PMID: 20572300 DOI: 10.3748/wjg.v16.i24.2978]

2 **Lauritano EC**, Gabrielli M, Scarpellini E, Lupascu A, Novi M, Sottili S, Vitale G, Cesario V, Serricchio M, Cammarota G, Gasbarrini G, Gasbarrini A. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. *Am J Gastroenterol* 2008; **103**: 2031-2035 [PMID: 18802998 DOI: 10.1111/j.1572-0241.2008.02030.x]

3 **Urita Y**, Watanabe T, Maeda T, Arita T, Sasaki Y, Ishii T, Yamamoto T, Kugahara A, Nakayama A, Nanami M, Domon K, Ishihara S, Kato H, Hike K, Hara N, Watanabe S, Nakanishi K, Sugimoto M, Miki K. Extensive atrophic gastritis increases intraduodenal hydrogen gas. *Gastroenterol Res Pract* 2008; **2008**: 584929 [PMID: 18795142 DOI: 10.1155/2008/584929]

4 **Ardatskaia MD**, Loginov VA, Minushkin ON. [Syndrome of bacterial overgrowth in patients with the reduced stomach acid secretion: some aspects of the diagnosis]. *Eksp Klin Gastroenterol* 2014;**(12)**: 30-36 [PMID: 26058109]

5 **Lo WK**, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. *Clin Gastroenterol Hepatol* 2013; **11**: 483-490 [PMID: 23270866 DOI: 10.1016/j.cgh.2012.12.011]

6 **Iivonen MK**, Ahola TO, Matikainen MJ. Bacterial overgrowth, intestinal transit, and nutrition after total gastrectomy. Comparison of a jejunal pouch with Roux-en-Y reconstruction in a prospective random study. *Scand J Gastroenterol* 1998; **33**: 63-70 [PMID: 9489910]

7 **Paik CN**, Choi MG, Lim CH, Park JM, Chung WC, Lee KM, Jun KH, Song KY, Jeon HM, Chin HM, Park CH, Chung IS. The role of small intestinal bacterial overgrowth in postgastrectomy patients. *Neurogastroenterol Motil* 2011; **23**: e191-e196 [PMID: 21324050 DOI: 10.1111/j.1365-2982.2011.01686.x]

8 **Petrone P**, Sarkisyan G, Fernández M, Coloma E, Akopian G, Ortega A, Kaufman HS. Small intestinal bacterial overgrowth in patients with lower gastrointestinal symptoms and a history of previous abdominal surgery. *Arch Surg* 2011; **146**: 444-447 [PMID: 21502453 DOI: 10.1001/archsurg.2011.55]

9 **Lakhani SV**, Shah HN, Alexander K, Finelli FC, Kirkpatrick JR, Koch TR. Small intestinal bacterial overgrowth and thiamine deficiency after Roux-en-Y gastric bypass surgery in obese patients. *Nutr Res* 2008; **28**: 293-298 [PMID: 19083422 DOI: 10.1016/j.nutres.2008.03.002]

10 **Roland BC**, Ciarleglio MM, Clarke JO, Semler JR, Tomakin E, Mullin GE, Pasricha PJ. Low ileocecal valve pressure is significantly associated with small intestinal bacterial overgrowth (SIBO). *Dig Dis Sci* 2014; **59**: 1269-1277 [PMID: 24795035 DOI: 10.1007/s10620-014-3166-7]

11 **Faria M**, Pavin EJ, Parisi MC, Lorena SL, Brunetto SQ, Ramos CD, Pavan CR, Mesquita MA. Delayed small intestinal transit in patients with long-standing type 1 diabetes mellitus: investigation of the relationships with clinical features, gastric emptying, psychological distress, and nutritional parameters. *Diabetes Technol Ther* 2013; **15**: 32-38 [PMID: 23126582 DOI: 10.1089/dia.2012.0158]

12 **Vantrappen G**, Janssens J, Hellemans J, Ghoos Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. *J Clin Invest* 1977; **59**: 1158-1166 [PMID: 864008]

13 **Pimentel M**, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. *Dig Dis Sci* 2002; **47**: 2639-2643 [PMID: 12498278 DOI: 10.1023/A: 1021039032413]

14 **George NS**, Sankineni A, Parkman HP. Small intestinal bacterial overgrowth in gastroparesis. *Dig Dis Sci* 2014; **59**: 645-652 [PMID: 23053897 DOI: 10.1007/s10620-012-2426-7]

15 **Reddymasu SC**, McCallum RW. Small intestinal bacterial overgrowth in gastroparesis: are there any predictors? *J Clin Gastroenterol* 2010; **44**: e8-13 [PMID: 20027008 DOI: 10.1097/MCG.0b013e3181aec746]

16 **Choung RS**, Ruff KC, Malhotra A, Herrick L, Locke GR, Harmsen WS, Zinsmeister AR, Talley NJ, Saito YA. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. *Aliment Pharmacol Ther* 2011; **33**: 1059-1067 [PMID: 21395630 DOI: 10.1111/j.1365-2036.2011.04625.x]

17 **Pignata C**, Budillon G, Monaco G, Nani E, Cuomo R, Parrilli G, Ciccimarra F. Jejunal bacterial overgrowth and intestinal permeability in children with immunodeficiency syndromes. *Gut* 1990; **31**: 879-882 [PMID: 2387510 DOI: 10.1136/gut.31.8.879]

18 **Klaus J**, Spaniol U, Adler G, Mason RA, Reinshagen M, Tirpitz C von C. Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's Disease. *BMC Gastroenterol* 2009; **9**: 61 [PMID: 19643023 DOI: 10.1186/1471-230X-9-61]

19 **Sánchez-Montes C**, Ortiz V, Bastida G, Rodríguez E, Yago M, Beltrán B, Aguas M, Iborra M, Garrigues V, Ponce J, Nos P. Small intestinal bacterial overgrowth in inactive Crohn's disease: influence of thiopurine and biological treatment. *World J Gastroenterol* 2014; **20**: 13999-14003 [PMID: 25320539 DOI: 10.3748/wjg.v20.i38.13999]

20 **Schatz RA**, Zhang Q, Lodhia N, Shuster J, Toskes PP, Moshiree B. Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients. *World J Gastroenterol* 2015; **21**: 4574-4582 [PMID: 25914466 DOI: 10.3748/wjg.v21.i15.4574]

21 **Gabbard SL**, Lacy BE, Levine GM, Crowell MD. The impact of alcohol consumption and cholecystectomy on small intestinal bacterial overgrowth. *Dig Dis Sci* 2014; **59**: 638-644 [PMID: 24323179 DOI: 10.1007/s10620-013-2960-y]

22 **Madrid AM**, Cumsille F, Defilippi C. Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease. *Dig Dis Sci* 1997; **42**: 738-742 [PMID: 9125642 DOI: 10.1023/A: 1018899611006]

23 **Chang CS**, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. *Hepatology* 1998; **28**: 1187-1190 [PMID: 9794900 DOI: 10.1002/hep.510280504]

24 **Pande C**, Kumar A, Sarin SK. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. *Aliment Pharmacol Ther* 2009; **29**: 1273-1281 [PMID: 19302262 DOI: 10.1111/j.1365-2036.2009.03994.x]

25 **Bauer TM**, Steinbrückner B, Brinkmann FE, Ditzen AK, Schwacha H, Aponte JJ, Pelz K, Kist M, Blum HE. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. *Am J Gastroenterol* 2001; **96**: 2962-2967 [PMID: 11693333 DOI: 10.1111/j.1572-0241.2001.04668.x]

26 **Wigg AJ**, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. *Gut* 2001; **48**: 206-211 [PMID: 11156641 DOI: 10.1136/gut.48.2.206]

27 **Lauritano EC**, Bilotta AL, Gabrielli M, Scarpellini E, Lupascu A, Laginestra A, Novi M, Sottili S, Serricchio M, Cammarota G, Gasbarrini G, Pontecorvi A, Gasbarrini A. Association between hypothyroidism and small intestinal bacterial overgrowth. *J Clin Endocrinol Metab* 2007; **92**: 4180-4184 [PMID: 17698907]

28 **Kumar K**, Ghoshal UC, Srivastava D, Misra A, Mohindra S. Small intestinal bacterial overgrowth is common both among patients with alcoholic and idiopathic chronic pancreatitis. *Pancreatology* 2014; **14**: 280-283 [PMID: 25062877 DOI: 10.1016/j.pan.2014.05.792]

29 **Sung HJ**, Paik CN, Chung WC, Lee KM, Yang JM, Choi MG. Small Intestinal Bacterial Overgrowth Diagnosed by Glucose Hydrogen Breath Test in Post-cholecystectomy Patients. *J Neurogastroenterol Motil* 2015; **21**: 545-551 [PMID: 26351251 DOI: 10.5056/jnm15020]

30 **Gardenbroek TJ**, Eshuis EJ, Ponsioen CI, Ubbink DT, D'Haens GR, Bemelman WA. The effect of appendectomy on the course of ulcerative colitis: a systematic review. *Colorectal Dis* 2012; **14**: 545-553 [PMID: 21689293 DOI: 10.1111/j.1463-1318.2011.02600.x]

**P-Reviewer:** Sinha RA **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Germany

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Basic characteristics**

|  | **SIBO** | | **Non-SIBO** | | χ**2 or Student’s *t*-test** |
| --- | --- | --- | --- | --- | --- |
| ***n* = 175** | **%** | ***n* = 1634** | **%** | ***P* value** |
| Age (yr) | 48.7 ± 17.9 | - | 49.3 ± 18.0 | - | 0.70 |
| Sex (female) | 107 | 61.1% | 924 | 56.5% | 0.139 |
| Pathological LHBT | 102 | 58.3% | 212 | 13.0% | < 0.0011 |
| Pathological GHBT | 146 | 83.4% | 9 | 0.6% | < 0.0011 |
| Diarrhoea | 72 | 41.1% | 648 | 39.7% | 0.380 |
| Constipation | 4 | 2.3% | 38 | 2.3% | 0.616 |
| Weight Loss | 39 | 22.3% | 313 | 19.2% | 0.185 |
| Malabsorption | 9 | 5.1% | 53 | 3.2% | 0.138 |
| Iron Deficiency Anaemia | 2 | 1.1% | 38 | 2.3% | 0.240 |
| Vitamin B12 Anaemia | 1 | 0.6% | 4 | 0.2% | 0.399 |
| Number of Drugs Used | 1.61 | - | 1.32 | - | 0.0051 |
| Supplementation of Folic Acid | 3 | 1.7% | 22 | 1.3% | 0.442 |
| Supplementation of Iron | 17 | 9.7% | 18 | 1.1% | 0.0221 |
| Supplementation of Vitamin B12 | 6 | 3.4% | 18 | 1.1% | 0.0231 |
| Abdominal Ultrasound | 152 | 86.9% | 1508 | 92.3% | 0.0221 |
| EGD | 120 | 68.6% | 1187 | 72.6% | 0.146 |
| Colonoscopy | 100 | 57.1% | 1069 | 65.4% | 0.0191 |
| Enteroclysis | 45 | 25.7% | 357 | 21.8% | 0.143 |
| Video Capsule Endoscopy | 7 | 4.0% | 19 | 1.2% | 0.0091 |
| Enteroscopy | 1 | 0.6% | 4 | 0.2% | 0.399 |

**1**Statistically significant with *P* value < 0.05 in χ2 or Student’s *t*-test. As expected, the SIBO group showed a pathological hydrogen breath test. Symptoms did not differ significantly. Patients with SIBO took more drugs and were more likely to supplement vitamin B12 or iron. During the hospital stay, patients with SIBO underwent small bowel diagnostic procedures more often, while patients without SIBO were more likely to undergo other diagnostic procedures. SIBO: Small intestinal bacterial overgrowth; LHBT: Lactulose Hydrogen Breath Test; GHBT: Glucose Hydrogen Breath Test; EGD: Esophagogastroduodenoscopy.

**Table 2 Hypo-/achlorhydria**

|  | **SIBO** | | **Non-SIBO** | | χ**2 test** | **OR** | **RR** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| ***n* = 175** | **%** | ***n* = 1634** | **%** | ***P* value** |
| Gastrectomy | 4 | 2.3% | 11 | 0.7% | 0.0491 | 3.451 | 0.295 |
| Atrophic Gastritis | 2 | 1.1% | 5 | 0.3% | 0.141 | - | - |
| PPI Therapy | 70 | 40.0% | 519 | 31.8% | 0.0341 | 1.432 | 0.794 |
| Ulcer Indicated PPI Therapy | 5 | 2.9% | 47 | 2.9% | 0.611 | - | - |
| Gastritis Indicated PPI Therapy | 20 | 11.4% | 195 | 11.9% | 0.481 | - | - |
| GERD Indicated PPI Therapy | 20 | 11.4% | 179 | 11.0% | 0.464 | - | - |
| Indicated PPI Therapy | 42 | 24.0% | 395 | 24.2% | 0.522 | - | - |
| Not Indicated PPI Therapy | 58 | 33.1% | 370 | 22.6% | 0.0021 | 1.728 | 0.693 |

**1**Statistically significant with *P* value < 0.05 in χ2 test. Patients with SIBO had a history of gastrectomy more often and were more likely to take PPI. In subgroup analysis, those patients who received PPI due to peptic ulcer disease, gastritis or GERD had the same risk of developing SIBO, while those patients who did not exhibit such indications had a 1.7-fold increased risk of showing SIBO. SIBO: Small intestinal bacterial overgrowth; PPI: Proton pump inhibitor; GERD: Gastroesophageal reflux disease.

**Table 3 Impaired clearance**

|  | **SIBO** | | **Non-SIBO** | | χ**2 test** | **OR** | **RR** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| ***n* = 175** | **%** | ***n* = 1634** | **%** | ***P* value** |
| Any Abdominal Surgery | 51 | 29.1% | 487 | 29.8% | 0.466 | - | - |
| Obstetric Surgery | 2 | 1.1% | 45 | 2.8% | 0.135 | - | - |
| Abdominal w/o Obstetric Surgery | 49 | 28.0% | 444 | 27.2% | 0.438 | - | - |
| Gastrectomy | 4 | 2.3% | 11 | 0.7% | 0.0491 | 3.451 | 0.295 |
| BII-Resection | 5 | 2.9% | 31 | 1.9% | 0.265 | - | - |
| Existence of Blind Loops | 8 | 4.6% | 41 | 2.5% | 0.0942 | 1.861 | 0.549 |
| Any Resecting Gastric Surgery | 12 | 6.9% | 45 | 2.8% | 0.0071 | 2.600 | 0.402 |
| Resection of Ileocecum | 7 | 4.0% | 41 | 2.5% | 0.176 | - | - |
| Appendectomy | 7 | 4.0% | 134 | 8.2% | 0.0271 | 0.466 | 2.050 |
| Functional Appendectomy | 14 | 8.0% | 175 | 10.7% | 0.163 | - | - |
| Cholecystectomy | 8 | 4.6% | 127 | 7.8% | 0.0782 | 0.568 | 1.700 |
| Resection of Small Intestine | 11 | 6.3% | 80 | 4.9% | 0.260 | - | - |
| Any Colonic Resection | 19 | 10.9% | 97 | 5.9% | 0.0131 | 1.930 | 0.547 |
| Sigmoid Resection | 3 | 1.7% | 13 | 0.8% | 0.196 | - | - |
| Vagotomy | 2 | 1.1% | 6 | 0.4% | 0.177 | - | - |
| Fistula | 2 | 1.1% | 16 | 1.0% | 0.532 | - | - |
| Stenosis | 10 | 5.7% | 29 | 1.8% | 0.0031 | 3.354 | 0.311 |
| Impaired Motility | 17 | 9.7% | 9 | 0.6% | < 0.0011 | 5.157 | 0.202 |
| Gastroparesis | 5 | 2.9% | 24 | 1.5% | 0.0301 | 3.403 | 0.300 |
| Neuropathy | 9 | 5.1% | 39 | 2.4% | 0.0371 | 2.217 | 0.464 |
| Opioid Use | 10 | 5.7% | 55 | 3.4% | 0.0902 | 1.740 | 0.589 |

1Statistical significant with *P*-value *P* < 0.05; 2Statistical tendency with *P*-value 0.05 < *P* < 0.1 χ2 test each. Overall abdominal surgery was not associated with an increased risk of developing SIBO. Resecting gastric surgery in general and gastrectomy was associated with the development of SIBO. Patients with SIBO were less likely to have a history of appendectomy and – as a tendency – cholecystectomy. Ileocecal resection had no impact on the development of SIBO. As a further anatomical alteration, stenoses were more frequent in SIBO patients. Impaired motility, as shown by gastroparesis, led to SIBO; patients with neuropathy or opioid medication are patients at risk.SIBO: Small intestinal bacterial overgrowth.

**Table 4 Immunological factors**

|  | **SIBO** | | **Non-SIBO** | | χ**2 test** | **OR** | **RR** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| ***n* = 175** | **%** | ***n* = 1634** | **%** | ***P* value** |  |  |
| IgA-deficiency | 0 of 6 | 0.0% | 13 of 75 | 17.3% | 0.337 | - | - |
| IgG-deficiency | 3 of 5 | 60.0% | 15 of 52 | 28.8% | 0.175 | - | - |
| IgM-deficiency | 0 of 5 | 0.0% | 15 of 54 | 21.7% | 0.311 | - | - |
| 5-Aminosalicylates | 24 | 13.7% | 183 | 11.2% | 0.191 | - | - |
| Steroid Use | 36 | 20.6% | 222 | 13.6% | 0.0101 | 1.647 | 0.660 |
| Immunosuppressant Use | 8 | 4.6% | 31 | 1.9% | 0.0291 | 2.477 | 0.415 |
| Azathioprin Use | 7 | 4.0% | 31 | 1.9% | 0.0672 | 2.155 | 0.474 |
| Metotrexate Use | 3 | 1.7% | 0 | 0.0% | 0.0011 | n/a | n/a |
| Any Drug-induced Immunosuppression | 39 | 22.3% | 230 | 14.1% | 0.0041 | 1.751 | 0.632 |
| Steroid Plus Immunosuppressant | 7 | 4.0% | 23 | 1.4% | 0.0211 | 2.918 | 0.352 |

1 Statistical significant with *P*-value *P* < 0.05; 2Statistical tendency with p-value 0.05 < *P* < 0.1 χ2 test each. Deficiencies of immunoglobulins were not associated with a higher prevalence of SIBO. On the other hand, pharmacologically induced immunosuppression with steroids alone, with an immunosuppressant alone or with both in combination lead to a higher risk of developing of SIBO.SIBO: Small intestinal bacterial overgrowth.

**Table 5 Miscellaneous variables**

|  | **SIBO** | | **Non-SIBO** | | χ**2 test** | **OR** | **RR** |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | ***n* = 175** | **%** | ***n* = 1634** | **%** | ***P* value** |
| Thyroid Gland Surgery | 7 | 4.0% | 33 | 2.0% | 0.0852 | 2.021 | 0.505 |
| Hypothyroidism | 17 | 9.7% | 66 | 4.0% | 0.0021 | 2.556 | 0.416 |
| Hyperthyroidism | 1 | 0.6% | 24 | 1.5% | 0.287 | - | - |
| Levothyroxine Use | 30 | 17.1% | 106 | 6.5% | < 0.0011 | 2.982 | 0.378 |
| Adipositas | 31 | 17.7% | 307 | 18.8% | 0.410 | - | - |
| Diabetes Mellitus | 25 | 14.3% | 132 | 8.1% | 0.0061 | 1.896 | 0.565 |
| Steatosis Hepatis | 22 | 12.6% | 158 | 9.7% | 0.139 | - | - |
| Hepatitis | 7 | 4.0% | 61 | 3.7% | 0.492 | - | - |
| Liver Cirrhosis | 2 | 1.1% | 35 | 2.1% | 0.289 | - | - |
| Renal Insufficiency | 2 | 1.1% | 16 | 1.0% | 0.532 | - | - |
| Colonic Diverticulosis | 6 | 3.4% | 37 | 2.3% | 0.229 | - | - |
| Sigmoid Diverticulosis | 8 | 4.6% | 151 | 9.2% | 0.0201 | 0.470 | 2.021 |
| Crohn’s disease | 19 | 10.9% | 134 | 8.2% | 0.146 | 1.363 | 0.755 |
| Ulcerative colitis | 2 | 1.1% | 52 | 3.2% | 0.0922 | 0.352 | 2.785 |
| Alcoholism | 3 | 1.7% | 36 | 2.2% | 0.468 | - | - |
| Smokers | 10 | 5.7% | 52 | 3.2% | 0.0702 | 1.844 | 0.557 |
| NSAID use | 29 | 16.6% | 284 | 17.4% | 0.442 | - | - |
| Laxative use | 3 | 1.7% | 58 | 3.5% | 0.142 | - | - |
| Antidiarrhoics use | 9 | 5.1% | 118 | 7.2% | 0.195 | - | - |
| Spasmolytics use | 9 | 5.1% | 257 | 15.7% | < 0.0011 | 0.290 | 3.058 |
| Antiemetics use | 22 | 12.6% | 144 | 8.8% | 0.0712 | 1.488 | 0.701 |
| Irritable bowel syndrome | 8 | 4.6% | 322 | 19.7% | < 0.0011 | 0.195 | 4.311 |

1Statistical significant with *P*-value *P* < 0.05; 2Statistical tendency with *P*-value 0.05 < *P* < 0.1 χ2 test each. Patients with hypothyroidism and substitution of levothyroxine show a higher risk of SIBO. In the case of thyroidectomy, statistical significance was not achieved. The presence of diverticulosis of the sigmoid, but not of the entire colon was associated with a decreased risk of SIBO. Patients with Crohn’s disease did not exhibit a higher prevalence of SIBO, and ulcerative colitis tended to be protective, but did not reach statistical significance. Patents without SIBO were more likely to use spasmolytics and to suffer from irritable bowel syndrome. SIBO: Small intestinal bacterial overgrowth; NSAID: Non-steroidal anti-inflammatory drugs.

**Table 6 Multivariate analysis**


| **Equation variables** | **Regression coefficient B** | **Wald** | **Significance** | **Exp (B)** | **95%CI for Exp (B)** | |
| --- | --- | --- | --- | --- | --- | --- |
| **Lower Limit** | **Upper Limit** |
| PPI Therapy | 0.241 | 2.015 | 0.156 | 1.273 | 0.912 | 1.776 |
| Gastrectomy | 0.600 | 0.676 | 0.411 | 1.821 | 0.436 | 7.604 |
| Any Resecting Gastric Surgery | 0.875 | 4.369 | 0.037 | 2.399 | 1.056 | 5.450 |
| Stenoses | 1.033 | 7.011 | 0.008 | 2.809 | 1.308 | 6.033 |
| Gastroparesis | 1.016 | 3.244 | 0.072 | 2.762 | 0.914 | 8.345 |
| Any Colon Resection | 0.479 | 3.012 | 0.083 | 1.614 | 0.940 | 2.772 |
| Any Medical Immunosuppression | 0.428 | 4.380 | 0.036 | 1.534 | 1.028 | 2.291 |
| Levothyroxine Therapy | 1.070 | 20.980 | 0.000 | 2.916 | 1.845 | 4.609 |
| Diabetes Mellitus | -0.453 | 3.223 | 0.073 | 0.636 | 0.388 | 1.042 |
| Sigmoid Diverticulosis | 0.832 | 4.835 | 0.028 | 2.298 | 1.095 | 4.823 |

Binary logistic regression analysis for risk factors for SIBO: SIBO: Small intestinal bacterial overgrowth. Exp: Exponent; CI: Confidence interval. All parameters found to be significant in previous analyses were used for analysis with binary logistic regression. A history of gastric surgery, stenoses, medical immunosuppression, levothyroxine therapy and sigmoid diverticulosis showed statistical significance as contributors to SIBO.

**Table 7 Binary logistic regression for categorised variables**

| **Equation variables** | **Regression coefficient B** | **Wald** | **Significance** | **Exp (B)** | **95%CI for Exp (B)** | |
| --- | --- | --- | --- | --- | --- | --- |
| **Lower Limit** | **Upper Limit** |
| Impaired Acid Barrier | 0.277 | 2.780 | 0.095 | 1.319 | 0.953 | 1.827 |
| Impaired Clearance | 0.772 | 14.463 | 0.0001 | 2.164 | 1.454 | 3.221 |
| Impaired Immune Response | 0.453 | 5.161 | 0.0231 | 1.572 | 1.064 | 2.324 |
| Hypothyroidism | 1.083 | 22.514 | 0.0001 | 2.953 | 1.888 | 4.620 |

1Regression analysis for categorised variables: CI: Confidence Interval. Exp (B): Exponent B. 1Statistically significant with *P* value < 0.05 in binary logistic regression. A simplified model, which included a leading factor of each pathophysiological pathway, revealed that, in ascending order, impaired immune response, impaired intestinal clearance and hypothyroidism are the key pathways for the development of SIBO.

****

**Figure 1 Study flow chart.** A total of3715 hydrogen breath examinations was eligible; 1586 were excluded due to missing or insufficient clinical data. From the remaining 2129 records, 320 were excluded because of multiple breath tests in the same subject, so that a summary total of 1809 patients were included in our study. 175 (9.7%) showed SIBO in terms, while 1634 did not (90.3%).